He's the first American Pope in history, but Leo XIV might not be able to escape the IRS
Even though Pope Leo XIV is the first American pontiff in history, he might still be subject to the Internal Revenue Service and have to file his tax return.
The native Chicagoan and baseball fan will likely need to get his finances in order with the IRS, like any other American, despite his new status as leader of 1.4 billion Catholics worldwide.
'The U.S. is one of few countries that taxes citizens on income made outside the U.S., so any U.S. citizen living and working abroad will face U.S. tax compliance concerns—even the Pope,' Shivam Malhotra, a partner at Atlanta-based accounting firm Aprio, said.
'The Pope may be one of the top-ranking religious leaders in the world, but the fact pattern for his U.S. tax liability is still very similar to a U.S. citizen working abroad as a member of the clergy,' Malhotra added.
U.S. citizens living abroad are required to file an annual tax return unless they renounce their citizenship. Because Leo is both a clergyman and now head of a foreign government – the Vatican – his tax situation is especially complex. Leo will have special tax considerations, but being a member of the clergy does not mean he is exempt entirely.
In general, U.S. citizens living overseas need to file a tax return if their income and personal circumstances would require them to do so 'in the same way as those residing in the United States,' the IRS says.
It doesn't necessarily mean that they would pay the same amount in taxes as they would living in the U.S. For individuals working abroad and earning less than $130,000 in the 2025 tax year, it's possible that they would owe no U.S. tax at all, Wise explains. But not all types of foreign incomes qualify for the exemption, including Leo, because his income is earned working for a foreign government.
While the pope does not earn a salary, housing, healthcare, food and travel are covered by the Vatican. The pope can also receive a monthly allowance for personal expenses.
Leo, therefore, may be required to calculate the value of his earnings.
'If he did accept his allowed salary, and if it weren't already exempt due to his diplomatic status, it would fall well under the threshold for the foreign earned income exclusion,' Malhotra said. 'And although the value of his lodging would not be eligible for the foreign earned housing exclusion, tax rules for clergy would still allow him to exclude that value from his income. However, the value of his food and transportation could, theoretically, be taxable.'
Experts told the Washington Post that Leo's situation is 'brand new territory' for the IRS and the Vatican, given America's 'far-reaching' tax laws.
Edward A. David, an assistant professor at King's College London's theology and religious studies department, told the Post said the situation was 'unprecedented.'
'U.S. tax law is very far-reaching. And while there might be an exemption for heads of state, this is brand-new territory for us and brand-new territory for the United States and the Vatican,' David told the newspaper.
Jared Walczak, a vice president of the Tax Foundation think tank, also told the outlet that he doesn't expect the pope to end up paying U.S. taxes.
The more likely outcome, Walczak speculated, is that the IRS will issue Leo a letter privately to address his situation, or Congress could pass a law outlining the tax situation for the pope.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
John Textor provides another twist in Crystal Palace ownership saga
The Crystal Palace ownership saga has taken another twist with the club's largest shareholder, John Textor, listing his holding company Eagle Football for an initial public offering in the US. Textor's multi-club operation, which also owns majority shares in Lyon and Botafogo, has submitted a draft registration statement to the US Securities and Exchange Commission. An IPO is when a private company first sells shares to the public. Eagle documents seen by the Guardian show that the company has made a confidential S-1 filing, with institutional investors invited to buy shares in it. Neither the volume nor prices of the shares to be listed has been made public. Eagle has sustained heavy losses in recent years largely due to its big spending at Lyon, rather than Palace. Textor first announced plans for an Eagle IPO, which would be the first conducted by a multi-club football group, with a company valuation of $2bn (£1.47bn) last November, but the timing of the listing is curious given his involvement in sale talks at Palace, and the uncertainty over whether the club will be allowed to compete in the Europa League next season. Textor declined to comment or discuss his intentions. Lyon have also qualified for the competition and Uefa rules prevent clubs with the same owners both taking part. As previously revealed by the Guardian, Uefa has rejected an offer by Textor to put his 44.9% stake in Palace into a blind trust as he missed the 1 March deadline, and the American has since stepped up his efforts to sell. The Guardian reported on Thursday that the New York Jets owner, Woody Johnson, has offered £190m to buy Textor's shares in a move that would be welcomed by the club chairman, Steve Parish, although that price is believed to be considerably short of his valuation. A consortium including NBA star Jimmy Butler and investment company Sportsbank has also made an offer. Textor's preference would be to sell to fellow shareholders Josh Harris and David Blitzer, who each own 18% of the club, but despite months of negotiations they have been unable to agree on a price. Textor has spent around £180m on Palace since buying an initial 40% stake for £87m four years ago, with his investment crucial to the redevelopment of the club's training ground and funding numerous player purchases, and is reluctant to sell at a big loss. Palace have expressed confidence they will be cleared by Uefa to take part in the Europa League on the grounds that Textor does not have a 'decisive influence' at the club, and if they are thrown out are likely to appeal to the court of arbitration for sport. Uefa made renewed contact with Palace seeking clarification on elements of their submissions last week, which the club have interpreted as a positive sign. In a potentially worrying development for Palace, Drogheda United were expelled from the Conference League last week due to multi-club issues. The Irish Premier League club are owner by the American investors Trivela Group, whose Danish club Silkeborg have also qualified for the competition and been given primacy by Uefa as they finished higher in their domestic league. Sign up to Football Daily Kick off your evenings with the Guardian's take on the world of football after newsletter promotion Drogheda responded by saying they will take the matter to Cas, and the Palace case also appears destined to be decided by the court in Lausanne. To complicate matters further, Nottingham Forest would be promoted from the Conference League to the Europa League if Palace are banned by Uefa. Forest have written to Uefa outlining their position and they, in turn, could take the matter to Cas if Palace are allowed to stay in the Europa League.
Reuters
an hour ago
- Reuters
Exclusive: US Export-Import Bank considers $120 million loan for Greenland rare earths project
June 15 (Reuters) - Critical Metals Corp (CRML.O), opens new tab has received a letter of interest from the U.S. Export-Import Bank (EXIM) for a loan worth up to $120 million to fund the company's Tanbreez rare earths mine in Greenland, in what would be the Trump administration's first overseas investment in a mining project. The loan, if approved, would boost U.S. access to minerals increasingly at the center of global economic trade and help offset the country's reliance on market leader China. It also comes after President Donald Trump openly mused earlier this year about acquiring the Danish island territory, an overture that has been repeatedly rejected. In a letter dated June 12 and reviewed by Reuters, New York-based Critical Metals has met initial requirements to apply for the $120 million EXIM loan and, if approved, would have a 15-year repayment term, longer than the company likely would have with private financing. The project would have to be "well-capitalized with sufficient equity from strategic investors" to receive the loan, the letter said. EXIM, which acts as the U.S. government's export credit agency, said in the letter that Critical Metals qualifies for a loan program designed to support companies that compete with China. The Tanbreez project is expected to cost $290 million and the EXIM funds would be used to fund technical work and get the mine to initial production by 2026. Once fully operational, the mine is expected to produce 85,000 metric tons per year of a rare earths concentrate and two minor metals. "This funding package is expected to unlock significant value for our project and our stakeholders," said Tony Sage, the company's CEO. Representatives for EXIM were not immediately available to comment. The move is the latest in a series of supportive actions by Washington toward the Tanbreez deposit and Greenland's mining sector. Reuters reported in January that former President Joe Biden's administration had successfully lobbied privately held Tanbreez Mining not to sell to a Chinese developer and instead sell to Critical Metals. Biden officials were visiting Nuuk as recently as last November trying to woo additional private investment, opens new tab in the island. Trump sent Vice President JD Vance to the island in March. The island's mining sector has developed slowly in recent years, hindered by limited investor interest, bureaucratic challenges and environmental concerns. Currently, only two small mines are in operation. Rare earths have strong magnetic properties that make them critical to high-tech industries ranging from electric vehicles to missile systems. Their necessity has given rise to intense competition as Western countries try to lessen their dependence on China's near-total control of their extraction and processing. Beijing in April put export restrictions on rare earths as part of its trade spat with Trump. The two countries earlier this month reached a truce, although Beijing's control of the sector has exacerbated the West's over-reliance and sparked a global hunt for fresh supplies. Despite the loan potential, Critical Metals would still have to either build a processing facility or find an existing site with spare capacity. The company told Reuters that its goal is to process the material inside the U.S., a goal the EXIM loan would make more achievable. Last year, Critical Metals had applied for funding to develop a processing facility from the U.S. Department of Defense, but the review process stalled ahead of Trump's January inauguration. For the EXIM loan's additional funding requirements, Critical Metals said it is considering offtake agreements, royalty streams and funding from other U.S. governmental agencies. Critical Metals told Reuters earlier this year that it has held supply talks with defense contractor Lockheed Martin (LMT.N), opens new tab, among others. Critical Metals' 10th-largest investor is brokerage firm Cantor Fitzgerald ( which was formerly led by Howard Lutnick before he joined Trump's cabinet as secretary of the U.S. Commerce Department. Sage told Reuters in January he had never met or talked to Lutnick, but acknowledged Cantor's investment was a positive for his company. EXIM last year extended a letter of interest to Perpetua Resources (PPTA.O), opens new tab for a loan worth up to $1.8 billion for its antimony and gold mine in Idaho.
Telegraph
2 hours ago
- Telegraph
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Non-US countries are 'free-riding' Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
